Hepatitis B virus infection, its sequelae, and prevention by vaccination

Current Opinion in Immunology

Volumn 23, Issue 2, 2011, Pages 237-243

  Huang, Li Min ^a,b   Lu, Chun Yi ^a,b   Chen, Ding Shinn ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; ANTIBODY TITER; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DRUG EFFICACY; DRUG SAFETY; ENVIRONMENTAL EXPOSURE; GENETIC POLYMORPHISM; HEPATITIS B; HUMAN; HUMORAL IMMUNITY; INNATE IMMUNITY; LIVER CELL CARCINOMA; NATURAL KILLER CELL; REVIEW; SEROCONVERSION; TH1 CELL; VACCINATION; VIRUS LOAD; VIRUS REPLICATION;

CARCINOMA, HEPATOCELLULAR; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; IMMUNITY, HUMORAL; LIVER NEOPLASMS;

EID: 79953123163     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2010.12.013     Document Type: Review

References (67)

1. World Health Organization. Hepatitis B. World Health Organization Fact Sheet 204 (Revised 2008). 2008 [cited 2010 Sep. 8]; Available from: http://www.who.int/mediacentre/factsheets/fs204/en/.
2. Beasley R.P., Hwang L.Y., Lin C.C., Chien C.S. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981, 2:1129-1133.
3. Chen D.S. From hepatitis to hepatoma: lessons from type B viral hepatitis. Science 1993, 262:369-370.
4. Lok A.S. Chronic hepatitis B. N Engl J Med 2002, 346:1682-1683.
5. Chen D.S. Natural history of chronic hepatitis B virus infection: new light on an old story. J Gastroenterol Hepatol 1993, 8:470-475.
6. Tsai S.L., Chen P.J., Lai M.Y., Yang P.M., Sung J.L., Huang J.H., Hwang L.H., Chang T.H., Chen D.S. Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion. J Clin Invest 1992, 89:87-96.
7. Yang H.I., Lu S.N., Liaw Y.F., You S.L., Sun C.A., Wang K.Y., Hsiao C.K., Chen P.J., Chen D.S., Chen C.H., et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002, 347:168-174.
8. Tsai W.L., Chung R.T. Viral hepatocarcinogenesis. Oncogene 2010, 29:2309-2324.
9. Bertoletti A., Gehring A.J. The immune response during hepatitis B virus infection. J Gen Virol 2006, 87:1439-1449.
10. Wieland S., Thimme R., Purcell R.H., Chisari F.V. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A 2004, 101:6669-6674.
11. Webster G.J., Reignat S., Maini M.K., Whalley S.A., Ogg G.S., King A., Brown D., Amlot P.L., Williams R., Vergani D., et al. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology 2000, 32:1117-1124.
12. Nakamura I., Nupp J.T., Cowlen M., Hall W.C., Tennant B.C., Casey J.L., Gerin J.L., Cote P.J. Pathogenesis of experimental neonatal woodchuck hepatitis virus infection: chronicity as an outcome of infection is associated with a diminished acute hepatitis that is temporally deficient for the expression of interferon gamma and tumor necrosis factor-alpha messenger RNAs. Hepatology 2001, 33:439-447.
13. Stevens C.E., Beasley R.P., Tsui J., Lee W.C. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 1975, 292:771-774.
14. Sobao Y., Tomiyama H., Sugi K., Tokunaga M., Ueno T., Saito S., Fujiyama S., Morimoto M., Tanaka K., Takiguchi M. The role of hepatitis B virus-specific memory CD8 T cells in the control of viral replication. J Hepatol 2002, 36:105-115.
15. Kamatani Y., Wattanapokayakit S., Ochi H., Kawaguchi T., Takahashi A., Hosono N., Kubo M., Tsunoda T., Kamatani N., Kumada H., et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet 2009, 41:591-595.
16. Guidotti L.G., Chisari F.V. Immunolbiology and pathogenesis of viral hepatitis. Ann Rev Pathol 2006, 1:23-61.
17. Wu J.F., Wu T.C., Chen C.H., Ni Y.H., Chen H.L., Hsu H.Y., Chang M.H. Serum levels of interleukin-10 and interleukin-12 predict early, spontaneous hepatitis B virus e antigen seroconversion. Gastroenterology 2010, 138:165-172.
18. Chen D.S. Hepatitis B vaccination: The key towards elimination and eradication of hepatitis B. J Hepatol 2009, 50:805-816.
19. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep 1991, 40:1-25.
20. Heyward W.L., Bender T.R., McMahon B.J., Hall D.B., Francis D.P., Lanier A.P., Alward W.L., Ahtone J.L., Murphy B.L., Maynard J.E. The control of hepatitis B virus infection with vaccine in Yupik Eskimos. Demonstration of safety, immunogenicity, and efficacy under field conditions. Am J Epidemiol 1985, 121:914-923.
21. Chen D.S., Hsu H.M., Sung J.L., Hsu T.C., Hsu S.T., Kuo Y.T., Lo K.J., Shih Y.T. A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers. JAMA 1987, 257:2597-2603. The Hepatitis Steering Committee, The Hepatitis Control Committee.
22. Hsu H.M., Chen D.S., Chang C.H., Lu J.C.F., Jwo D.M., Lee C.C., Lu H.C., Cheng S.H., Wang T.F., Wang C.C., et al. Efficacy of a mass hepatitis B vaccination program in Taiwan: studies on 3464 infants of hepatitis B surface antigen carrier mothers. JAMA 1988, 260:2231-2235.
23. Kane M. Global programme for control of hepatitis B infection. Vaccine 1995, 13:S47-S49.
24. Milne A., West D.J., Chinh D.V., Moyes C.D., Poerschke G. Field evaluation of the efficacy and immunogenicity of recombinant hepatitis B vaccine without HBIG in newborn Vietnamese infants. J Med Virol 2002, 67:327-333.
25. Lolekha S., Warachit B., Hirunyachote A., Bowonkiratikachorn P., West D.J., Poerschke G. Protective efficacy of hepatitis B vaccine without HBIG in infants of HBeAg-positive carrier mothers in Thailand. Vaccine 2002, 20:3739-3743.
26. Greenberg D.P. Pediatric experience with recombinant hepatitis B vaccines and relevant safety and immunogenicity studies. Pediatr Infect Dis J 1993, 12:438-445.
27. Pongpipat D., Suvatte V., Assateerawatts A. Hepatitis B immunization in high risk neonates born from HBsAg positive mothers: comparison between plasma derived and recombinant DNA vaccine. Asian Pac J Allergy Immunol 1989, 7:37-40.
28. Niu M.T., Rhodes P., Salive M., Lively T., Davis D.M., Black S., Shinefield H., Chen R.T., Ellenberg S.S. Comparative safety of two recombinant hepatitis B vaccines in children: data from the Vaccine Adverse Event Reporting System (VAERS) and Vaccine Safety Datalink (VSD). J Clin Epidemiol 1998, 51:503-510.
29. McMahon B.J., Helminiak C., Wainwright R.B., Bulkow L., Trimble B.A., Wainwright K. Frequency of adverse reactions to hepatitis B vaccine in 43,618 persons. Am J Med 1992, 92:254-256.
30. Marshall E. A shadow falls on hepatitis B vaccination effort. Science 1998, 81:630-631.
31. Hernan M.A., Jick S.S., Olek M.J., Jick H. Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. Neurology 2004, 63:838-842.
32. Zipp F., Weil J.G., Einhaupl K.M. No increase in demyelinating diseases after hepatitis B vaccination. Nat Med 1999, 5:64-965.
33. Sadovnick A.D., Scheifele D.W. School-based hepatitis B vaccination programme and adolescent multiple sclerosis. Lancet 2000, 355:549-550.
34. Duclos P. Safety of immunization and adverse events following vaccination against hepatitis B. J Hepatol 2003, 39:83s-88s.
35. West D.J., Calandra G.B. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine 1996, 14:1019-1027.
36. Hwang L.Y., Beasley R.P., Stevens C.E., Szmuness W. Immunogenicity of HBV vaccine in healthy Chinese children. Vaccine 1983, 1:10-12.
37. Lee C.Y., Huang L.M., Chang M.H., Hsu C.Y., Wu S.J., Sung J.L., Safary A. The protective efficacy of recombinant hepatitis B vaccine in newborn infants of hepatitis B e antigen-positive-hepatitis B surface antigen carrier mothers. Pediatr Infect Dis J 1991, 10:299-303.
38. Koff R.S. Immunogenicity of hepatitis B vaccines: implications of immune memory. Vaccine 2002, 20:3695-3701.
39. Fujisawa T., Onoue M., Inui A., Kosugi T. Serial changes in titers of antibody to hepatitis B surface antigen after immunization of infants born to mothers with hepatitis B e antigen. J Pediatr Gastroenterol Nutr 1996, 23:270-274.
40. Mast E.E., Weinbaum C.M., Fiore A.E., Alter M.J., Bell B.P., Finelli L., Rodewald L.E., Douglas J.M., Janssen R.S., Ward J.W. Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC), A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006, 55:1-33. quiz CE1-4.
41. Stevens C.E., Toy P.T., Taylor P.E., Lee T., Yip H.Y. Prospects for control of hepatitis B virus infection: implications of childhood vaccination and long-term protection. Pediatrics 1992, 90:170-173.
42. Williams I.T., Goldstein S.T., Tufa J., Tauillii S., Margolis H.S., Mahoney F.J. Long term antibody response to hepatitis B vaccination beginning at birth and to subsequent booster vaccination. Pediatr Infect Dis J 2003, 22:157-163.
43. Kao J.H., Chen D.S. Hepatitis B vaccination: to boost or not to boost?. Lancet 2005, 366:1337-1338.
44. Banatvala J., Van Damme P., Oehen S. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine 2000, 19:877-885.
45. Jan C.F., Huang K.C., Chien Y.C., Greydanus D.E., Davies H.D., Chiu T.Y., Huang L.M., Chen C.J., Chen D.S. Determination of immune memory to hepatitis B vaccination through early booster response in college students. Hepatology 2010, 51:1547-1554.
46. Huang L.M., Chiang B.L., Lee C.Y., Lee P.I., Chi W.K., Chang M.H. Long-term response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen. Hepatology 1999, 29:954-959.
47. Lu C.Y., Chiang B.L., Chi W.K., Chang M.H., Ni Y.H., Hsu H.M., Twu S.J., Su I.J., Huang L.M., Lee C.Y. Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination. Hepatology 2004, 40:1415-1420.
48. Chang M.H., Chen C.J., Lai M.S., Hsu H.M., Wu T.C., Kong M.S., Liang D.C., Shau W.Y., Chen D.S. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997, 336:1855-1859. The Taiwan Childhood Hepatoma Study Group.
49. Chang M.H., You S.L., Chen C.J., Liu C.J., Lee C.M., Lin S.M., Chu H.C., Wu T.C., Yang S.S., Kuo H.S., et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009, 101:1348-1355.
50. Wichajarn K., Kosalaraksa P., Wiangnon S. Incidence of hepatocellular carcinoma in children in Khon Kaen before and after national hepatitis B vaccine program. Asian Pac J Cancer Prev 2008, 9:507-509.
51. Chang M.H. Breakthrough HBV infection in vaccinated children in Taiwan: surveillance for HBV mutants. Antivir Ther 2010, 15:463-469.
52. Mast E.E., Margolis H.S., Fiore A.E., Brink E.W., Goldstein S.T., Wang S.A., Moyer L.A., Bell B.P., Alter M.J. Advisory Committee on Immunization Practices (ACIP), A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005, 54:1-31.
53. Hsu H.Y., Chang M.H., Liaw S.H., Ni Y.H., Chen H.L. Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan. Hepatology 1999, 30:1312-1317.
54. Whittle H., Jaffar S., Wansbrough M., Mendy M., Dumpis U., Collinson A., Hall A. Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. BMJ 2002, 325:569.
55. European Consensus Group on Hepatitis B Immunity Are booster immunisations needed for lifelong hepatitis B immunity?. Lancet 2000, 355:561-565.
56. Ding L., Zhang M., Wang Y., Zhou S., Kong W., Smego R.A. A 9-year follow-up study of the immunogenicity and long-term efficacy of plasma-derived hepatitis B vaccine in high-risk Chinese neonates. Clin Infect Dis 1993, 17:475-479.
57. Lee P.I., Lee C.Y., Huang L.M., Chang M.H. Long-term efficacy of recombinant hepatitis B vaccine and risk of natural infection in infants born to mothers with hepatitis B e antigen. J Pediatr 1995, 126:716-721.
58. Kao J.T., Wang J.H., Hung C.H., Yen Y.H., Hung S.F., Hu T.H., Lee C.M., Lu S.N. Long-term efficacy of plasma-derived and recombinant hepatitis B vaccines in a rural township of Central Taiwan. Vaccine 2009, 27:1858-1862.
59. Lu C.Y., Ni Y.H., Chiang B.L., Chen P.J., Chang M.H., Chang L.Y., Su I.J., Kuo H.S., Huang L.M., Chen D.S., et al. Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after neonatal immunization. J Infect Dis 2008, 197:1419-1426.
60. McMahon B.J., Bruden D.L., Petersen K.M., Bulkow L.R., Parkinson A.J., Nainan O., Khristova M., Zanis C., Peters H., Margolis H.S. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med 2005, 142:333-341.
61. Yuen M.F., Lim W.L., Chan A.O., Wong D.K., Sum S.S., Lai C.L. 18-year follow-up study of a prospective randomized trial of hepatitis B vaccinations without booster doses in children. Clin Gastroenterol Hepatol 2004, 2:941-945.
62. But D.Y., Lai C.L., Lim W.L., Fung J., Wong D.K., Yuen M.F. Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: final report. Vaccine 2008, 26:6587-6591.
63. McMahon B.J., Dentinger C.M., Bruden D., Zanis, Peters H., Hurlburt D., Bulkow L., Fiore A.E., Bell B.P., Hennessy T.W. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis 2009, 200:1390-1396.
64. Poorolajal J., Mahmoodi M., Majdzadeh R., Nasseri-Moghaddam S., Haghdoost A., Fotouhi A. Long-term protection provided by hepatitis B vaccine and need for booster dose: a meta-analysis. Vaccine 2010, 28:623-631.
65. Hennig B.J., Fielding K., Broxholme J., Diatta M., Mendy M., Moore C., Pollard A.J., Rayco-Solon P., Sirugo G., van der Sande M.A., et al. Host genetic factors and vaccine-induced immunity to hepatitis B virus infection. PLoS One 2008, 3:e1898.
66. Chen D.S. Long-term protection of hepatitis B vaccine: lessons from Alaskan experience after 15 years. Ann Intern Med 2005, 142:384-385.
67. John T.J., Cooksley G. Hepatitis B vaccine boosters: is there a clinical need in high endemicity populations?. J Gastroenterol Hepatol 2005, 20:5-10.